Friday, 8 November 2013

China Advertising Industry Report, 2013

Reportstack has announced a new market research publication on China Advertising Industry Report, 2013. China's advertising industry from 2012 to the first half of 2013 showed the following characteristics:

Traditional media kit advertising growth has slowed down, touching its lowest level in the five years.

Due to macroeconomic impact, the Chinese traditional media kit (television, radio, newspapers and outdoor) advertising market witnessed a tiny year-on-year increase of 4.5% in 2012, touching its lowest level in the recent five years, of which, newspaper advertising reached an overall market size of approximately RMB 68.55 billion, down 12.6% YoY, the first negative growth over the past decade. In the first quarter of 2013, the Chinese newspaper advertising market size continued to fall, a year-on-year decline of about 12%.

Internet advertising has seen rapid development, with market size in 2012 up 46.83% YoY

China's internet advertising market size attained to RMB 75.31 billion in 2012, a year-on-year increase of 46.83%, and then slowed down to RMB 19.84 billion in the first quarter of 2013, with year-on-year growth of the first quarter firstly less than 40% for three consecutive years, entering into a relatively slackened growth cycle after high-speed development. Concerning the internet advertising revenue scale by enterprise, Baidu held the first position; Youku Tudou after the merger ranked eighth with revenue up to RMB 429 million in the first quarter of 2013.

China Advertising Industry Report, 2013  mainly includes the followings:

Development status, policy environment, advertisers change and market competition of advertising industry in China;
Market size, market segments, advertisers change and enterprise competition of internet advertising in China, as well as operation and advertising revenue of 11 major online advertising media companies including Baidu, Taobao, Google, Tencent, Sohu, Sina, Youku Tudou, SouFun, Qihoo 360, CBSi and NetEase;
Market size, market segments, advertisers change of newspaper advertising in China, as well as operation and advertising revenue of four major newspaper advertising media companies, i.e. Shanghai XinHua Media Co., Ltd., Chengdu B-Ray Media Co., Ltd., Huawen Media Investment Corporation and Zhejiang Daily Media Group Co., Ltd.;
China's outdoor advertising market size as well as operation and advertising revenue of four leading outdoor advertising media companies, i.e. Focus Media Holding Limited, AirMedia Group Inc., DHA Group and Clear Media Limited;
China's TV & radio advertising market size as well as operation and advertising revenue of five major TV & radio advertising media companies - China Television Media, Ltd., Shanghai Media Group, Hunan TV & Broadcast Intermediary Co., Ltd., Jiangsu Broadcasting Corporation and Zhejiang Broadcasting Corporation. 

To view the table of contents and know more details please visit China Advertising Industry Report, 2013.

Global and China Needle Coke Industry Report,2012-2015

Reportstack has announced a new market research publication on Global and China Needle Coke Industry Report,2012-2015. Needle coke mainly finds application in graphite electrode for electric steelmaking and in areas of lithium battery, nuclear power, aerospace, etc. Since 2009, the global demand for needle coke has shoot up in the wake of the gradual recovery in the industrial downstream. During the same period, the world’s industrial magnates have taken no actions to expand their capacities in a massive scale, out of consideration for holding precedence in prices, leading to lingeringly strained supply all over the world with the supply-demand gap in 2012 hitting 100,000 tons. In particular, China was the most distinctive with the short supply gapping 120,000 tons among the world’s leading needle coke consumers.

As the largest steel producer in the world, China has been maintaining huge demand for needle cokes. Moreover, ultra-high power graphite electrode is occupying increasing proportion as a result of continuously optimizing product structure in the graphite electrode industry, which, in turn, further fuels the demand for needle cokes. At the same time, China has smaller amount of needle coke enterprises which feature weak technological base and are huddled by the uncertainty of stable production and product quality. Thus, the needle coke capacity in China has seen slow growth with the supply gap increasingly widening. In 2009-2012, China’s demand for needle coke soared from 161,000 tons to 360,000 tons with the CAGR of 30.8% while the annual capacity surged from 130,000 tons to 240,000 tons with the CAGR of 22.7%. Given that most new industrial players encounter technical huddles and that industrial veterans witness limited capacity growth, the supply shortage is projected to go on in the upcoming two years.

As China is rich in coal and poor in oil, the supply of coal-based needle coke raw materials is abundant and China is technologically advanced in this regard. Nationwide, the existing needle coke capacity and most of planned and ongoing needle coke capacities are coal based needle cokes rather than oil-based needle cokes. Presently, large-sized ultra-high power graphite electrode products have become the mainstream in the graphite electrode industry. Because of its unique properties, oil-based needle cokes are ideal to make large-sized ultra-high power graphite electrode products. Hence, China needle coke market is witnessing structural imbalance between supply and demand.

Internationally, oil-based needle coke production technology is dominated by the US, Britain and Japan while the coal-based needle coke production technology is monopolized by Japan. ConocoPhillips, the world’s biggest producer of oil-based needle coke, realizes the needle coke capacity of 370,000 tons/a and the figure keeps stable in recent years. And the tycoon serves as one of benchmark makers when it comes to the oil-based needle coke prices globally.

Seadrift is the world’s second largest oil-based needle coke maker with the capacity recording 150,000 tons/a. In 2012, it was taken over by GTI, America’s largest graphite electrode manufacturer. According to GTI planning, the long-term capacity of the company will reach 240,000-25,000 tons/a.

C-Chem is a professional carbon product maker under Nippon Steel, and the world’s largest coal-based needle coke producer. In recent years, its needle coke capacity has greatly boosted through capacity expansion with the figure in 2012 soaring to 170,000 tons/a.

Shanxi Hongte Coal Chemical Industry is a coal-based needle coke enterprise in China, the first realized commercial production. In response to domestically robust demand, the company began its 100,000-ton coal-based needle coke project in 2008 which was put into operation in 2012 with the current capacity of 150, 000tons/a.

In Jun., 2011, the bidding of SINO Steel Anshan Research Institute of Thermal Energy’s second phase of needle coke project drew the curtain. According to real market demand, the company adjusted the capacity of the second phase to 120,000 tons/a. Meanwhile, the feasibility study and environmental assessment of the second phase had been done in 2012. And it is estimated to be put into production in 2014.

The report conducts an in-depth analysis on the development background and market pattern of global and China needle coke industry, highlights the business performance of 16 large industrial players at home and abroad, and predicts the development trend of the industry.

To view the table of contents and know more details please visit Global and China Needle Coke Industry Report,2012-2015.

China Feedstuff Industry Report, 2012-2015

Reportstack has announced a new market research publication on China Feedstuff Industry Report, 2012-2015. In 2011, China became the world's largest feedstuff producer with an output of 179 million tons. The feedstuff output increased by 6.4% year on year to 191 million tons in 2012, including 161.70 million tons of compound feed (representing a year-on-year increase of 8.4%), 23.50 million tons of concentrated feed (down 7.6% year on year) and 6.2 million tons of premixed feed (up 2.5% year on year).

By the competition pattern, China feedstuff industry is perfectly competitive, with a low profit margin. In 2012, the overall gross margin of Chinese feedstuff processing enterprises was 11% and the overall net profit margin reached 5.2%, representing absolute and relative lower levels compared with other sub-sectors of agriculture, forestry, animal husbandry and fishery.

After the long-term market competition, the fittest survive, and China feedstuff industry has formed the market competition pattern where the national market is dominated by a minority of national conglomerates, regional markets are led by some medium-sized enterprises and a large number of small companies play supporting roles. In 2012, the total sales volume of livestock, aquaculture and ruminant feedstuff of top 10 Chinese feed companies hit more than 54.90 million tons, accounting for 28.7% of China’s total in 2012.

New Hope Liuhe is engaged in feedstuff, breeding, meat products and financial investment. The company operates its business throughout the country and has set up or been building more than 20 branches and subsidiaries in Vietnam, the Philippines, Bangladesh, Indonesia, Cambodia, Sri Lanka, Singapore, Egypt and other countries.

Tangrenshen acts as one of leading national agricultural industrialization enterprises. Adhering to "breeder pigs, feed and meat products" as three main businesses, the company is committed to the integration of the pig industrial chain. It has over 40 subsidiary companies across China, of which 36 are feedstuff companies, with total feedstuff capacity of nearly 6 million tons.

Tongwei Co., Ltd. focuses on the feedstuff business, and is also involved in aquaculture, meat processing, animal health care as well as new energy, with more than 80 branches and subsidiaries engaged in feedstuff production and marketing throughout China and Southeast Asia. With an annual feedstuff capacity of 7 million tons, it has become the world's largest aquatic feedstuff producer and a major livestock and poultry feed enterprise in China.

China Feedstuff Industry Report 2012-2015 covers the following aspects:

Operation, policies, market supply and demand as well as competition patterns of China feedstuff industry by product;
Analysis on upstream raw materials and downstream breeding industry of China feedstuff industry, including output, sales volume, supply and demand of soybean meal, corn, wheat and additives;
Development trends of China feedstuff industry in terms of aquaculture feedstuff, industrial penetration and feedstuff industrial chain;
Operation, profitability and feedstuff business and outlook of 10 major feedstuff companies such as New Hope, Zhengbang Technology, Tangrenshen and DBN.

To view the table of contents and know more details please visit China Feedstuff Industry Report, 2012-2015.

Enterobacteriaceae Infections - Pipeline Review, H2 2013

Reportstack has announced a new market report on Enterobacteriaceae Infections - Pipeline Review, H2 2013 which provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Enterobacteriaceae Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterobacteriaceae Infections. Enterobacteriaceae Infections - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team of members.

Scope

- A snapshot of the global therapeutic scenario for Enterobacteriaceae Infections.
- A review of the Enterobacteriaceae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Enterobacteriaceae Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Enterobacteriaceae Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Enterobacteriaceae Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

The Companies Mentioned in this report are Achaogen Inc. Trana Discovery, Inc. Da Volterra.

To view the table of contents and know more details please visit Enterobacteriaceae Infections - Pipeline Review, H2 2013 report.

Chagas Disease (American Trypanosomiasis) - Pipeline Review, H2 2013

Reportstack has announced a new market report on Chagas Disease (American Trypanosomiasis) - Pipeline Review, H2 2013 which provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Chagas Disease (American Trypanosomiasis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chagas Disease (American Trypanosomiasis). Chagas Disease (American Trypanosomiasis) - Pipeline Review, Half Year is built using data and information sourced from databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team of members.

Scope

- A snapshot of the global therapeutic scenario for Chagas Disease (American Trypanosomiasis).
- A review of the Chagas Disease (American Trypanosomiasis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chagas Disease (American Trypanosomiasis) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chagas Disease (American Trypanosomiasis).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chagas Disease (American Trypanosomiasis) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

The Companies Mentioned in this report are Eisai Co., Ltd. PepTcell Limited Georgia Tech Research Corporation.

To view the table of contents and know more details please visit  Chagas Disease (American Trypanosomiasis) - Pipeline Review, H2 2013 report.

Cerebral Palsy - Pipeline Review, H2 2013

Reportstack has announced a new market report on Cerebral Palsy - Pipeline Review, H2 2013 which provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cerebral Palsy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cerebral Palsy. Cerebral Palsy - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team of members.

Scope

- A snapshot of the global therapeutic scenario for Cerebral Palsy.
- A review of the Cerebral Palsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cerebral Palsy pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cerebral Palsy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cerebral Palsy pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

The Companies Mentioned in this report are Allergan, Inc. ViaCord Acorda Therapeutics, Inc. Neuralstem, Inc. CHA Bio & Diostech Co., Ltd. RNL BIO Co., Ltd.

To view the table of contents and know more details please visit Cerebral Palsy - Pipeline Review, H2 2013 report

Cardiomyopathy - Pipeline Review, H2 2013

Reportstack has announced a new market report on Cardiomyopathy - Pipeline Review, H2 2013 which provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cardiomyopathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cardiomyopathy. Cardiomyopathy - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team of members.

Scope

- A snapshot of the global therapeutic scenario for Cardiomyopathy.
- A review of the Cardiomyopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cardiomyopathy pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cardiomyopathy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cardiomyopathy pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

The Companies Mentioned in this report are Torrent Pharmaceuticals Limited LG Life Sciences, Ltd Fibrotech Therapeutics Pty. Ltd. Beech Tree Labs, Inc. FCB-Pharmicell Co.,Ltd.

To view the table of contents and know more details please visit Cardiomyopathy - Pipeline Review, H2 2013 report.